Publications & Meeting Presentations

Access Scientific References for Our Pipeline Below

Enobosarm

Obesity

Prado et al., (2024, June). “Potential to Optimize Weight Loss with Enobosarm: Meta-analysis of Body Composition from Three Randomized Clinical Trials Support the Ability of Enobosarm to Preserve Muscle while Reducing Fat”. Poster presented at the 2024 American Diabetes Association in Orlando, FL.

June 2024|

Dobs et al., (2024, June). “Pooled Safety Analysis of Enobosarm from Phase 2 and Phase 3 Placebo-Controlled Clinical Trials”. Poster presented at the 2024 American Diabetes Association in Orlando, FL.

June 2024|

Crawford et al., (2024, May). “Potential to Optimize Weight Loss with Enobosarm: Augment Reduction of Fat Mass while Preserving Muscle in Older Patients with Obesity”. Poster presented at the 2024 American Association of Clinical Endocrinology, New Orleans, LA.

May 2024|

Crawford et al., (2024, May). “Double-Blind, Multiple Ascending Dose, Safety, Pharmacokinetic and Body Composition Study of Enobosarm in Healthy Young and Older Men”. Poster presented at the 2024 American Association of Clinical Endocrinology, New Orleans, LA.

May 2024|

Steiner et al., (2024, May). “Advancing enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs for potentially higher quality weight loss”. Slides presented at the 2024 GLP-1-Based Therapeutics Summit in Philadelphia, PA.

May 2024|

Barnette al., (2024, May). “A Phase 2 Trial to Evaluate the Effect on Body Composition and Safety of Enobosarm in Patients Treated with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Chronic Weight Management”. Poster presented at the 2024 GLP-1-Based Therapeutics Summit in Philadelphia, PA.

May 2024|

K O Böker et al., Treatment of osteoporosis using a selective androgen receptor modulator ostarine in an orchiectomized rat model. Endocrine. 2023 Sep;81(3):579-591.

September 2023|

Komrakova et al., Effect of Selective Androgen Receptor Modulator Enobosarm on Bone Healing in a Rat Model for Aged Male Osteoporosis. Calcif Tissue Int.. 2020 Dec;107(6):593-602.

December 2020|

Leciejewska et al., Effect of ostarine (enobosarm/GTX024), a selective androgen receptor modulator, on adipocyte metabolism in Wistar rats. J Physiol Pharmacol . 2019 Aug;70(4).

August 2019|

Hoffmann et al., Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. J Bone Miner Metab. 2019 Mar;37(2):243-255.

March 2019|

Narayanan et al., Development of Selective Androgen Receptor Modulators (SARMs). Mol Cell Endocrinol. 2018 Apr 15; 465: 134–142.

April 2018|

Crawford et al., Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials). Curr Oncol Rep. 2016 Jun;18(6):37

June 2016|

Dobs et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. Lancet Oncol. 2013 Apr;14(4):335-45.

April 2013|

Dalton et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle. 2011 Sep;2(3):153-161.

September 2011|

Kearbey et al., Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats. Pharm Res. 2007 Feb;24(2):328-35.

February 2007|

Gao et al., Selective Androgen Receptor Modulator Treatment Improves Muscle Strength and Body Composition and Prevents Bone Loss in Orchidectomized Rats. Endocrinology. 2005 Nov; 146(11): 4887–4897.

November 2005|

Cancer

Palmieri et al., Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial. Lancet Oncol. 2024 Mar;25(3):317-325.

March 2024|

Hickey et al., The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021 Feb;27(2):310-320.

February 2021|

Sabizabulin

Barnette et al., Oral Sabizabulin for High-Risk, Hospitalized Adults with Covid-19: Interim Analysis. NEJM Evid 2022;1(9).

July 2022|

Markowski M et al. A Phase Ib/II study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor targeting agent. Clin Can Res 2022, doi:10.1158/1078-0432.CCR-22-0162.

July 2022|

Gordon M et al. Phase II study of oral sabizabulin for the treatment of SARS-CoV-2 in hospitalized patients at high risk for ARDS. ECCMID, April 23, 2022.

April 2022|

Foyez M et al. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer Cancer Letters 495:76, 2020.

December 2020|

Deng S et al. An orally available tubulin inhibitor, VERU-111, suppresses triple negative breast cancer tumor growth and metastasis and bypasses taxane resistance. Mol Cancer Ther 19:348-363, 2020.

February 2020|

Kashyap VK et al. VERU-111 suppresses tumor growth and metastatic phenotype of cervical cancer cells through activation of p53 signaling pathway. Cancer Letters 470:64-74, 2020.

February 2020|

Kashyap VK et al. Therapeutic efficacy of novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer. J Exp Clin Can Res 38:29, 2019.

January 2019|

Li CM et al. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer. Pharm Res 29:3053-3063, 2012.

November 2012|

Chen J et al. Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents. J Med Chem 55:7285-7289, 2012.

August 2012|